The clinical efficacy of T-DXd in HER2-mutant NSCLC has been demonstrated in several trials such as DESTINY-Lung01 (Li et al., 2022), DESTINY-Lung02 (Goto et al., 2023), and DESTINY-Lung05 (Cheng et al., 2024). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.